Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes
Teplizumab can be safely and effectively administered in clinical practice. Early glycaemic improvements and reductions in CD4 preproinsulin-specific TCRs suggest that post-treatment immunological changes may serve as biomarkers to guide early-stage intervention.
Authors
- Taylor M. Triolo (ORCID: https://orcid.org/0000-0003-4796-6542)
- Aaron W. Michels (ORCID: https://orcid.org/0000-0003-3766-5244)
- Kagan Ege Karakus (ORCID: https://orcid.org/0000-0002-8552-5206)
- Erin E. Baschal (ORCID: https://orcid.org/0000-0002-8936-434X)
- Peter A. Gottlieb
- Lexie Chesshir
- Sonya Walker
- Kimber M. Simmons
- Kristen A. McDaniel
Institutions
- University of Colorado Denver (US)
Publication Details
- Journal
- Diabetologia
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1007/s00125-025-06646-6
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Leona M. and Harry B. Helmsley Charitable Trust
- National Institutes of Health